The Last Generation of Per-Seat Pharma Software

In January 2026, your company probably approved an IT budget that allocates somewhere between $2 million and $15 million to quality and manufacturing software — QMS licensing, MES seats, validation costs, integration projects. That budget was built on an assumption that has been true for twenty years: software is priced per user, and more users means more cost.

That assumption is now wrong. And the consequences for pharma IT spending are going to be severe.

In February 2026, more than $1 trillion in market capitalisation was erased from SaaS companies in seven days. Salesforce fell 38% year-to-date. ServiceNow dropped over 20%. The S&P 500 Software & Services Index shed roughly 30% in six weeks. AlixPartners estimates that $500 billion in enterprise software revenue is at risk as AI agents begin replacing the tools knowledge workers relied on.

This isn’t a tech-sector problem. This is a pharma budget problem. Because the software you’re paying for — per seat, per user, per named license — is built on an economic model that AI is about to invert.

Let me make the economics concrete with a scenario most VP Quality leaders will recognise.

A large pharma manufacturer with 10 manufacturing sites runs Veeva QualityOne across the organisation. Based on published benchmarks, a global Veeva deployment for 5,500 users costs approximately $142 per user per month — $7.2 million per year in licensing alone. That excludes implementation, validation, integration, and ongoing administration.

At each site, the QA team uses the QMS to manage deviations, CAPAs, change controls, complaints, and document management. The software itself doesn’t investigate deviations. It doesn’t write root cause analyses. It doesn’t assess whether a CAPA actually prevented recurrence. It routes work to humans, tracks that humans did the work, and reports on how long it took.

The actual quality work — the investigation, the analysis, the corrective action — is performed by your QA team. BioPhorum data shows that a minor deviation alone consumes 18.1 hours of activity time and 29 calendar days to close. McKinsey estimates 30% of pharma staff time goes to documentation. The fully loaded cost of a QA specialist in the US is $89,000–$129,000 per year.

So here’s the real cost equation: you’re paying $7.2 million per year for software that orchestrates $40–60 million per year in human labour. The software cost is 12–15% of the total. The labour is 85–88%.

Per-seat pricing makes sense when the work requires humans. When AI agents can perform the investigation, draft the root cause analysis, recommend the corrective action, and present a complete package for human approval — the labour compresses by 50–80%. And when labour compresses, you need fewer humans. When you need fewer humans, you need fewer seats.

The vendor’s revenue model is directly coupled to your headcount. A QMS vendor that successfully deploys AI is actively destroying its own revenue base. This is the innovator’s dilemma in its most literal form.

While pharma software vendors are still debating whether to add AI features to their per-seat platforms, the broader enterprise software market has already begun the pricing transition.

Intercom — the customer support platform — launched its AI agent “Fin” priced at $0.99 per resolution. You pay only when the AI successfully resolves a customer issue without human intervention. That model grew from $1 million to over $100 million ARR at a 393% annualised growth rate. Fin now handles over 80% of support volume and resolves 1 million customer issues per week. Intercom offers a $1 million performance guarantee — if the AI doesn’t hit resolution targets, they pay you.

Salesforce launched Agentforce with consumption-based “Flex Credits” — each AI agent action costs roughly $0.10, purchased in packs. The per-user model still exists alongside it, but the direction is unmistakable.

Zendesk prices its AI agents at $1.50–$2.00 per automated resolution. Chargeflow takes 25% of successfully recovered chargeback revenue — pure outcome alignment.

The pattern is consistent: charge for what the AI does, not for how many humans access the system.

And the market is responding. According to PricingSaaS’s 500 Index, 79 companies now offer credit-based pricing models, up from 35 at end of 2024 — a 126% increase in one year. Seat-based pricing adoption dropped from 21% to 15% in the same period, with churn rates 2.3x higher for companies that stick with per-seat models. 65% of SaaS vendors have started incorporating usage-based pricing alongside seat-based models.

Gartner predicts that by 2030, at least 40% of enterprise SaaS spending will shift to usage-, agent-, or outcome-based pricing.

Let me translate the Intercom model to pharmaceutical quality operations.

Today, your QMS charges approximately $150–$300 per user per month. For a site with 50 QA users, that’s $90,000–$180,000 per year in licensing — just for the right to access the system where your team does the actual work.

Now imagine a platform that charges per quality outcome:

The numbers are illustrative, but the direction is precise. In every scenario, outcome-based pricing delivers the same or better quality results at 40–60% lower total cost — because the pricing model is aligned with what actually matters: the resolution, not the headcount.

Foundation Capital calls this the shift from “Software-as-a-Service” to “Service-as-Software.” The addressable market expands from the ~$500 billion software market to the $4.6 trillion global services market — because you’re no longer selling tool access, you’re selling the outcome the tool was supposed to enable.

For pharma specifically, this means the QMS market isn’t a $2 billion category competing with other $2 billion categories. It’s a quality operations market worth tens of billions — if you measure it by outcomes delivered rather than seats licensed.

Here’s the conversation that pharma CFOs will face within the next 12–18 months — and most aren’t prepared for it.

The current budget structure: Pharma companies spend approximately 3.2% of revenue on IT infrastructure (Gartner benchmark). The global life sciences IT market is $26.3 billion in 2025, projected to reach $67.7 billion by 2034. Quality and manufacturing software — QMS, MES, LIMS — represents a significant slice. These budgets are approved annually, locked into multi-year contracts, and measured by deployment metrics (users onboarded, sites live, modules activated).

The incoming disruption: AI agents don’t need seats. They don’t need named licenses. They don’t need per-site deployments. An AI agent running on an LLM that costs $0.40 per million tokens (GPT-4 equivalent performance, down from $20 in late 2022) can process a deviation investigation for pennies in compute cost. McKinsey estimates the gen AI opportunity in biopharma operations at $4–$7 billion annually.

The budget reallocation: SaaStr observes that “every dollar going to AI infrastructure, AI tooling, AI headcount is a dollar NOT going to another Salesforce seat, another Workday module, another ServiceNow add-on.” The same applies to pharma: every dollar going to an AI agent platform is a dollar not going to QMS seat renewals.

75% of CFOs expect technology budgets to rise in 2026, with 48% anticipating increases of 10%+ (CIO Dive). But the composition of that spend is shifting dramatically. More on AI platforms and agents, less on per-seat enterprise software. The total IT budget grows. The allocation to legacy QMS shrinks.

This creates an uncomfortable dynamic for QMS vendors. Their customers’ IT budgets are growing — but the growth is going to their competitors. Every renewal conversation becomes a negotiation where the customer says: “Why am I paying $7 million per year for a system that routes work to humans, when I can pay $3 million per year for a platform where AI agents do the work?”

The QMS vendor’s only response is to add AI features. But as I argued in my previous piece, bolting AI onto a CRUD database doesn’t change the architecture — and it certainly doesn’t change the pricing model. A vendor can’t offer $0.99-per-deviation pricing when their entire revenue model depends on $142-per-seat-per-month renewals. They would cannibalise themselves.

There’s a deeper problem with per-seat QMS pricing that goes beyond economics. The pricing model creates perverse incentives that actually undermine quality.

Consider how per-seat licensing works in practice at a manufacturing site:

The transition won’t happen overnight. Multi-year enterprise contracts, validation requirements, and change management all create legitimate friction. But the economic pressure is now extraordinary, and it moves in one direction only.

McKinsey’s analysis of 150 global software vendors found that “well-funded AI-native start-ups are resetting the bar with dynamic, usage-aligned pricing models that offer buyers greater control, transparency, and scalability.” EY warns that “software companies face a more complex future as pricing shifts from the traditional seat basis to a hybrid of seat, consumption and outcome models.”

The per-seat model had a good run. It aligned vendor revenue with customer growth for two decades. But when AI agents do the work that humans used to do, the model breaks. Fewer humans. Fewer seats. Less revenue. The math is simple, and it’s already priced into public software valuations.

Your QMS vendor will try to hold the line on per-seat pricing for as long as possible — it’s rational behaviour when your revenue model depends on it. Your job as a quality leader is to recognise that their pricing incentives are no longer aligned with your operational interests, and to start planning for the model that replaces it.

Because the last generation of per-seat pharma software is the one you’re running right now.